Yeul Hong Kim, MD, PhD

home / authors / yeul-hong-kim-md-phd

Articles

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

Daniel V. T. Catenacci, MD;Yoon-Koo Kang, MD, PhD;Hope E. Uronis, MD, MHS;Keun-Wook Lee, MD, PhD;Matthew C. H. Ng, MD;Peter C. Enzinger, MD;Se Hoon Park, MD, PhD;Philip J. Gold, MD;Jill Lacy, MD;Howard S. Hochster, MD;Sang Cheul Oh, MD, PhD;Yeul Hong Kim, MD, PhD;Kristen A. Marrone, MD;Ronan J. Kelly, MD;Rosalyn A. Juergens, MD;Jong Gwang Kim, MD, PhD;Thierry Alcindor, MD, MSc;Sun Jin Sym, MD, PhD;Eun-Kee Song, MD, PhD;Cheng Ean Chee, MD;Yee Chao, MD, PhD;Sunnie Kim, MD;Do-Youn Oh, MD, PhD;Jennifer Yen, PhD;Justin I. Odegaard, MD, PhD;Errin Lagow, PhD;Daner Li, MS;Jichao Sun, PhD;Patrick Kaminker, PhD;Paul A. Moore, PhD;Minori Koshiji Rosales, MD, PhD;Haeseong Park, MD, MPH
April 27th 2023

Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.

Latest Updated Articles

Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes
Published: August 26th 2011 | Updated: December 22nd 2024
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes
A 51-Year-Old Patient Develops Scaly Plaque on the Right Foot
Published: October 14th 2013 | Updated: December 22nd 2024
A 51-Year-Old Patient Develops Scaly Plaque on the Right Foot